Phio Pharmaceuticals Corp.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $4.6M | $3.6M | $6.3M | $7.0M | $8.9M |
| Operating expenses | $9.2M | $7.4M | $10.8M | $11.5M | $13.5M |
| Operating income | -$9.2M | -$7.4M | -$10.8M | -$11.5M | -$13.5M |
| Pretax income | — | — | — | -$11.5M | -$13.3M |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$8.7M | -$7.2M | -$10.8M | -$11.5M | -$13.3M |
| Balance Sheet | |||||
| Cash and equivalents | $21.0M | $5.4M | $8.5M | — | — |
| Current assets | $21.5M | $5.7M | $9.3M | $12.4M | $24.7M |
| Total assets | $21.5M | $5.7M | $9.4M | $12.8M | $25.2M |
| Current liabilities | — | $1.0M | $1.6M | $1.9M | $3.1M |
| Total liabilities | $1.3M | $1.0M | $1.6M | $2.0M | $3.2M |
| Stockholders' equity | $20.1M | $4.7M | $7.7M | $10.8M | $21.9M |
| Cash Flow Statement | |||||
| Cash from operations | -$8.0M | -$7.1M | -$10.7M | -$12.1M | -$11.9M |
| Depreciation and amortization | $3,000 | $2,000 | $56,000 | $71,000 | $75,000 |
| Stock-based compensation | $481,000 | $147,000 | $303,000 | $414,000 | $480,000 |
| Capital expenditure | $12,000 | $1,000 | $5,000 | $121,000 | $51,000 |
| Free cash flow | -$8.0M | -$7.1M | -$10.8M | -$12.2M | -$11.9M |
| Impairments | — | $0 | $126,000 | $0 | $0 |
Shares outstanding 11.6M · Free float 63.9%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.